About: Middle East respiratory syndrome: obstacles and prospects for vaccine development

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Middle East respiratory syndrome: obstacles and prospects for vaccine development Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Middle East respiratory syndrome: obstacles and prospects for vaccine development
Creator	Jahrling, Peter Johnson, Reed Wada, Jiro Papaneri, Amy Bollinger, Laura Kuhn, Jens
topic	covid:c9f8a0a6ee96deb896a2dcb0a19c3eb76074a22d#this
Source	Medline; PMC
abstract	The recent emergence of Middle East respiratory syndrome (MERS) highlights the need to engineer new methods for expediting vaccine development against emerging diseases. However, several obstacles prevent pursuit of a licensable MERS vaccine. First, the lack of a suitable animal model for MERS complicates in vivo testing of candidate vaccines. Second, due to the low number of MERS cases, pharmaceutical companies have little incentive to pursue MERS vaccine production as the costs of clinical trials are high. In addition, the timeline from bench research to approved vaccine use is 10 years or longer. Using novel methods and cost-saving strategies, genetically engineered vaccines can be produced quickly and cost-effectively. Along with progress in MERS animal model development, these obstacles can be circumvented or at least mitigated.
has issue date	2015-04-11(xsd:dateTime)
bibo:doi	10.1586/14760584.2015.1036033
bibo:pmid	25864502
has license	bronze-oa
sha1sum (hex)	c9f8a0a6ee96deb896a2dcb0a19c3eb76074a22d
schema:url	https://doi.org/10.1586/14760584.2015.1036033
resource representing a document's title	Middle East respiratory syndrome: obstacles and prospects for vaccine development
has PubMed Central identifier	PMC4832601
has PubMed identifier	25864502
schema:publication	Expert Review of Vaccines
resource representing a document's body	covid:c9f8a0a6ee96deb896a2dcb0a19c3eb76074a22d#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/c9f8a0a6ee96deb896a2dcb0a19c3eb76074a22d
is schema:about of	named entity 'NOVEL' named entity 'RECENT' named entity 'PHARMACEUTICAL' named entity 'STRATEGIES' named entity 'YEARS' named entity 'NUMBER OF' named entity 'production' named entity 'Along' named entity 'diseases' named entity 'However' named entity 'MERS' named entity 'COST' named entity 'MIDDLE EAST RESPIRATORY SYNDROME' named entity 'IN VIVO TESTING' named entity 'SUITABLE' named entity 'MIDDLE EAST RESPIRATORY SYNDROME ' named entity 'BENCH' named entity 'ADDITION' named entity 'METHODS' named entity 'DISEASES' named entity 'NEED' named entity 'GENETICALLY ENGINEERED' named entity 'TIMELINE' named entity 'VACCINE' named entity 'ANIMAL MODEL' named entity 'COSTS' named entity 'HAVE' named entity 'SECOND' named entity 'APPROVED' named entity 'LOW' named entity 'INCENTIVE' named entity 'LITTLE' named entity 'VACCINE DEVELOPMENT' named entity 'DUE TO' named entity 'USE' named entity 'VACCINE DEVELOPMENT' named entity 'EMERGENCE' named entity 'LACK' named entity 'MODEL DEVELOPMENT' named entity 'PREVENT' named entity 'PROGRESS' named entity 'USING' named entity 'MERS VACCINE' named entity 'MERS' named entity 'HIGH' named entity 'CANDIDATE' named entity 'ENGINEER' named entity 'VACCINE PRODUCTION' named entity 'NEW' named entity 'THESE' named entity 'RESEARCH' named entity 'CASES' named entity 'COMPANIES' named entity 'CLINICAL TRIALS' named entity 'VACCINES' named entity 'candidate' named entity 'vivo' named entity 'genetically engineered' named entity 'prospects' named entity 'genetically engineered' named entity 'MERS' named entity 'animal model' named entity 'vaccine' named entity 'MERS' named entity 'vaccine' named entity 'incubation period' named entity 'abdominal pain' named entity 'MERS-CoV' named entity 'nonvirulent' named entity 'Ebola' named entity 'renal failure' named entity 'virus' named entity 'Australia' named entity 'infection'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software